In PDA, mutant KRAS promotes the reprogramming of glutamine metabolism through a GOT1- and GOT2-mediated transamination pathway instead of the pathway catalyzed by GLUD1 [8]. Here, GOT2 is linked to Patent ductus arteriosus.